Download PDF
Thromb Haemost 1997; 77(04): 735-740
DOI: 10.1055/s-0038-1656043
Platelets
Schattauer GmbH Stuttgart

Thrombin Interaction with Platelet GPIB: Role of the Heparin Binding Domain

Erica De Candia
1   The Centro Ricerche Fisiopatologia dell’Emostasi, Istituto di Semeiotica Medica, Università Cattolica S. Cuore, Roma, Italia
,
Raimondo De Cristofaro
1   The Centro Ricerche Fisiopatologia dell’Emostasi, Istituto di Semeiotica Medica, Università Cattolica S. Cuore, Roma, Italia
,
Lulgi De Marco
Servizio Immunotrasfusionale e Analisi Cliniche, Centro di Riferimento Oncologico, Aviano, Pordenone, Italia
,
Moreno Mazzucato
Servizio Immunotrasfusionale e Analisi Cliniche, Centro di Riferimento Oncologico, Aviano, Pordenone, Italia
,
Matilde Picozzi
1   The Centro Ricerche Fisiopatologia dell’Emostasi, Istituto di Semeiotica Medica, Università Cattolica S. Cuore, Roma, Italia
,
Raffaele Landolfi
1   The Centro Ricerche Fisiopatologia dell’Emostasi, Istituto di Semeiotica Medica, Università Cattolica S. Cuore, Roma, Italia
› Author Affiliations
Further Information

Publication History

Received 25 June 1996

Accepted after revision 25 November 1996

Publication Date:
11 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

The platelet membrane glycoprotein lb (Gplb) has a high affinity binding site for α-thrombin whose occupancy is thought to positively modulate the thrombin-induced platelet activation. In this study, aimed at further characterizing the thrombin-GpIb interaction, two thrombin anion exosites referred to as “heparin binding site” (HBS) and “fibrino#gen recognition site” (FRS) were investigated as the possible domains involved in Gplb binding. The role of thrombin HBS was explored by performing binding measurements of 125I-α-thrombin to purified glycocalicin (GC), the extracytoplasmic portion of Gplb, in the presence of heparin as well as after chemical modifications of the thrombin heparin binding site (thrombin-HBS phosphopyridoxylation). These studies showed that a) thrombin binding to GC could be competitively inhibited by heparin and b) the equilibrium association constant for thrombin-GC interaction was reduced up to ten-fold by chemical modifications at the HBS. On the other hand, the role of FRS in the thrombin-GC interaction could be excluded by other experiments showing that GC in solution could not influence the interaction of α-thrombin with two substrates which bind to both the catalytic site and the fibrinogen recognition site: 1) the thrombin receptor peptide 38-60 (TR, L38-E60) and 2) the A α-chain of fibrinogen. Altogether these results demonstrated that GC interaction with thrombin involves the enzyme heparin binding site, whereas the fibrinogen recognition site does not play a significant role.

 

  • References

  • 1 vVu T-K, Hung D, Wheaton V, Coughlin S. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanisms of receptor activation. Cell 1991; 64: 1057-1068
    CrossrefPubMedGoogle Scholar
  • 2 Gralnick HR, Williams LP, McKeown K, Hansmann JW, Fenton II JW, Krutzsch H. High affinity thrombin binding to platelet glycoprotein lb: identificationof two binding domains. Proc Natl Acad Sci USA 1994; 91: 6334-6338
    CrossrefPubMedGoogle Scholar
  • 3 De Marco L, Mazzucato M, Masotti A, Fenton II JW, Ruggeri ZM. Function of glycoprotein Ibα in platelet activation induced by α-thrombin. J Biol Chem 1991; 266: 23776-23783
    PubMedGoogle Scholar
  • 4 Harmon JT, Jamieson GA. Platelet activation by thrombin in the absence of the high affinity thrombin receptor. Biochemistry 1988; 27: 2151-2157
    CrossrefPubMedGoogle Scholar
  • 5 Jamieson GA, Okumura T. Reduced thrombin binding and aggregation in Bemard-Soulier platelets. J Clin Invest 1978; 61: 861-864
    CrossrefPubMedGoogle Scholar
  • 6 Jandrot-Perrus M, Clemetson KJ, Huisse M-G, Guillin MC. Thrombin interaction with platelet glycoprotein lb: effect of glycocalicin on thrombin specificity. Blood 1992; 80: 2781-2786
    PubMedGoogle Scholar
  • 7 Ternisien C, Jandrot-Perrus M, Huisse M-G, Guillin M-C. Effect of phos-phopyridoxylation on thrombin interaction with platelet glycoprotein lb. Blood Coag Fibrinol 1991; 02: 521-528
    CrossrefPubMedGoogle Scholar
  • 8 Mathews II, Padmanabhan KP, Ganesh V, Tulinsky A, Ishii M, Chen J, Turck CW, Coughlin SR, Fenton JW. Crystallographic structures of thrombin complexed with thrombin receptor peptides: existence of expected and novel binding modes. Biochemistry 1994; 33: 3266-3279
    CrossrefPubMedGoogle Scholar
  • 9 Vu T-K, Wheaton VI, Hung DT, Charo I, Coughlin SR. Domains specific-ing thrombin-receptor interaction. Nature (London) 1991; 353: 674-677
    CrossrefPubMedGoogle Scholar
  • 10 Bode W, Turk D, Karshikov A. The refined 1.9 A X-ray crystall structure of d-Phe-Pro-Arg chloro methyl ketone-inhibited human α-thrombin: structure analysis, overall structure, electrostatic properties, detailed active site geometry, and structure-function relationships. Protein Sci 1992; 01: 426-471
    PubMedGoogle Scholar
  • 11 White G, Lundblad RL, Griffith MJ. Structure-function relations in platelet-thrombin reactions. J Biol Chem 1981; 256: 1763-1766
    PubMedGoogle Scholar
  • 12 Handa M, Titani K, Holland LZ, Roberts JR, Ruggeri ZM. The von Wille-brand factor-binding domain of platelet membrane glycoprotein lb. J Biol Chem 1986; 261: 12579-12585
    PubMedGoogle Scholar
  • 13 De Cristofaro R, Rocca B, Bizzi B, Landolfi R. The linkage between binding of the C-terminal domain of hirudin and amydase activity in human α-thrombin. Biochem J 1993; 289: 475-480
    CrossrefPubMedGoogle Scholar
  • 14 Church FC, Pratt CW, Noyes CM, Kalayanamit T, Sherrill GB, Tobin RB, Meade JB. Structural and functional properties of human α-thrombin, phos-phopyridoxylated α-thrombin and gammarthrombin. J Biol Chem 1989; 264: 18419-18425
    PubMedGoogle Scholar
  • 15 Griffith MJ. Covalent modification of human a-thrombin with pyridoxal 5`-phosphate. J Biol Chem 1979; 254: 3401-3406
    PubMedGoogle Scholar
  • 16 Griffith MJ. Kinetics of the heparin-enhanced antithrombin Ill/thrombin reaction. J Biol Chem 1982; 257: 7360-7365
    CrossrefPubMedGoogle Scholar
  • 17 Solum NO, Hagen I, Filion-Myklebust C, Stabaek T. Platelet glycocalicin. Its membrane association and solubilization in acqueous media. Biochem Biophys Acta 1980; 597: 235-246
    CrossrefPubMedGoogle Scholar
  • 18 Gill SC, von HippelP. Calculation of protein extinction coefficients from amino acid sequence data. Anal Biochem 1989; 182: 319-326
    CrossrefPubMedGoogle Scholar
  • 19 Lopez JA, Chung DW, Fujikawa K, Hagen FS, Papayannoopoulou T, Roth GJ. Cloning of the a chain of human platelet glycoprotein lb: a transmembrane protein with homology to leucin-rich a2-glycoprotein. Proc Natl Acad Sci USA 1987; 84: 5615-5619
    CrossrefPubMedGoogle Scholar
  • 20 De Marco L, Mazzucato M, Masotti A, Ruggeri ZM. Localization and characterization of an α-thrombin binding site on platelet glycoprotein Ibα. J Biol Chem 1994; 269: 6478-6484
    PubMedGoogle Scholar
  • 21 Marchese P, Murata M, Mazzucato M, Pradella P, De MarcoL, Ware J, Ruggeri ZM. Sulfation of tyrosine residues in the aminoterminal domain of platelet glycoprotein lb influences von Willebrand factor and a thrombin binding and can be detected with a monoclonal antibody. J Biol Chem 1995; 16: 9571-9578
    PubMedGoogle Scholar
  • 22 Munson PJ, Rodbard D. LIGAND: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 1980; 107: 220-239
    CrossrefPubMedGoogle Scholar
  • 23 Higgins DL, Lewis SD, Shafer JA. Steady state kinetic parameters for the thrombin-catalyzed conversion of human fibrinogen to fibrin. J Biol Chem 1983; 258: 9276-9282
    PubMedGoogle Scholar
  • 24 Picozzi M, Landolfi R, De CristofaroR. Effects of protons on thrombin-fibrinogen interactions. Eur J Biochem 1994; 219: 1013-1021
    CrossrefPubMedGoogle Scholar
  • 25 Fersth A. Enzyme structure and mechanism. Freeman; New York, NY: 1985. p 99
    Google Scholar
  • 26 Lewis SD, Shields PP, Shafer JA. Characterization of the kinetic pathway for liberation of fibrinopeptides during assembly of fibrin. J Biol Chem 1985; 260: 10192-10199
    PubMedGoogle Scholar
  • 27 Mihalyi E. Clotting of bovine fibrinogen. Calcium binding to fibrin during clotting and its dependence on release of fibrinopeptide B. Biochemistry 1988; 27: 967-976
    CrossrefPubMedGoogle Scholar
  • 28 Gan Z-R, Li Y, Chen Z, Lewis SD, Shafer JA. Identification of basic ami-noacid residues in thrombin essential for heparin-catalyzed inactivation by antithrombin III. J Biol Chem 1994; 269: 1301-1305
    PubMedGoogle Scholar
  • 29 Sheehan JP, Sadler JE. Molecular mapping of the heparin binding exosite of thrombin. Proc Natl Acad Sci USA 1994; 91: 5518-5522
    CrossrefPubMedGoogle Scholar
  • 30 Arni RK, Padmanabhan K, Padmanabhan KP, Wu T-P, Tulinsky A. Structures of the noncovalent complexes of human and bovine prothrombin Fragment 2 with human PPACK-thrombin. Biochemistry 1993; 32: 4727-4737
    CrossrefPubMedGoogle Scholar
  • 31 Workman EF Jr EF, White II GC, Lundblad RL. High affinity binding of thrombin to platelets. Inhibition by tetranitromethane and heparin. Biochem Biophys Res Comm 1977; 75: 925-932
    CrossrefPubMedGoogle Scholar
  • 32 Bouton MC, Jandrot-Perrus M, Moog S, Cazenave JP, Guillin MC, Lanza F. Thrombin interaction with recombinant N-terminal extracellular domain of the thrombin receptor in an acellular system. Biochem J 1995; 305: 635-641
    CrossrefPubMedGoogle Scholar
  • 33 De Cristofaro R, Di Cera E. The phenomenological analysis of the clotting curve. J Prot Chem 1991; 10: 455-468
    CrossrefPubMedGoogle Scholar
  • 34 Coughlin SR, Vu T-K, Hung DT, Wheaton WI. Characterization of a functional thrombin receptor. J Clin Invest 1992; 89: 351-355
    CrossrefPubMedGoogle Scholar
  • 35 Greco NJ, Tandon NN, Jones GD, Kornhauser R, Jackson B, Yamamoto N, Tanoue K, Jamieson GA. Contributions of Glycoprotein lb and the seven transmembrane domain receptor to increases in platelet cytoplasmic [Ca2+] induced by alpha-thrombin. Biochemistry 1996; 35: 906-914
    CrossrefPubMedGoogle Scholar
  • 36 Levine MN, Hirsh J. Haemorrhagic complications of anticoagulant therapy. Semin Thromb Haemost 1986; 12: 39-57
    Article in Thieme ConnectPubMedGoogle Scholar
  • 37 Fernandez F, Guyen P, van Ryn-McKenna J, Ofosu F, Hirsh J, Buchanan M. Haemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect. Thromb Res 1986; 43: 491-495
    CrossrefPubMedGoogle Scholar
  • 38 Theroux P, Ouimet H, McCans J, Latour JG, Joly P, Levy G, Pelletier E, Juneau M, Stasiak J, deGuise P, Pelletier GB, Rinzler D, Waters DD. Aspirin, Heparin, or both to treat unstable angina. N Engl J Med 1988; 319: 1105-1111
    CrossrefPubMedGoogle Scholar
  • 39 Tolefsen DM, Blinder MA, Hepa rin. In: Hematology. Basic principles and practice Hoffman R, Benz Jr EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE. eds. Churchill Livingstone; New York, NY: 1995. pp. 1802-1813